246 related articles for article (PubMed ID: 33298590)
1. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
Balog A; Lin TA; Maley D; Gullo-Brown J; Kandoussi EH; Zeng J; Hunt JT
Mol Cancer Ther; 2021 Mar; 20(3):467-476. PubMed ID: 33298590
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
3. Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
Hamilton MM; Mseeh F; McAfoos TJ; Leonard PG; Reyna NJ; Harris AL; Xu A; Han M; Soth MJ; Czako B; Theroff JP; Mandal PK; Burke JP; Virgin-Downey B; Petrocchi A; Pfaffinger D; Rogers NE; Parker CA; Yu SS; Jiang Y; Krapp S; Lammens A; Trevitt G; Tremblay MR; Mikule K; Wilcoxen K; Cross JB; Jones P; Marszalek JR; Lewis RT
J Med Chem; 2021 Aug; 64(15):11302-11329. PubMed ID: 34292726
[TBL] [Abstract][Full Text] [Related]
4. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.
Steeneck C; Kinzel O; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Czekańska M; Hoffmann T
Bioorg Med Chem Lett; 2021 Feb; 33():127744. PubMed ID: 33333163
[TBL] [Abstract][Full Text] [Related]
6. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors.
Naing A; Eder JP; Piha-Paul SA; Gimmi C; Hussey E; Zhang S; Hildebrand V; Hosagrahara V; Habermehl C; Moisan J; Papadopoulos KP
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843490
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Tang K; Wu YH; Song Y; Yu B
J Hematol Oncol; 2021 Apr; 14(1):68. PubMed ID: 33883013
[TBL] [Abstract][Full Text] [Related]
10. Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold.
Kinzel O; Steeneck C; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Wang Y; Mallinger A; Czekańska M; Hoffmann T
Bioorg Med Chem Lett; 2021 Feb; 33():127738. PubMed ID: 33316404
[TBL] [Abstract][Full Text] [Related]
11. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
12. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
Shi JG; Bowman KJ; Chen X; Maleski J; Leopold L; Yeleswaram S
J Clin Pharmacol; 2017 Jun; 57(6):720-729. PubMed ID: 27990653
[TBL] [Abstract][Full Text] [Related]
15. Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
Grobben Y; de Man J; van Doornmalen AM; Muller M; Willemsen-Seegers N; Vu-Pham D; Mulder WR; Prinsen MBW; de Wit J; Sterrenburg JG; van Cauter F; den Ouden JE; van Altena AM; Massuger LF; Uitdehaag JCM; Buijsman RC; Zaman GJR
Front Immunol; 2020; 11():609490. PubMed ID: 33584686
[TBL] [Abstract][Full Text] [Related]
16. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
17. Targeting the IDO1 pathway in cancer: from bench to bedside.
Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1.
Cherney EC; Zhang L; Nara S; Zhu X; Gullo-Brown J; Maley D; Lin TA; Hunt JT; Huang C; Yang Z; Darienzo C; Discenza L; Ranasinghe A; Grubb M; Ziemba T; Traeger SC; Li X; Johnston K; Kopcho L; Fereshteh M; Foster K; Stefanski K; Fargnoli J; Swanson J; Brown J; Delpy D; Seitz SP; Borzilleri R; Vite G; Balog A
ACS Med Chem Lett; 2021 Feb; 12(2):288-294. PubMed ID: 33603977
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
